STAT3 in Pancreatic Cancer Metastasis

  • Rongala Laxmivandana
  • Prudhvi Lal Bhukya
  • Maddala Madhavi
Chapter

Abstract

Pancreatic cancer is one of the leading causes of mortality associated with cancer. Signal transducer and activator of transcription (STAT)3 is implicated in metastasis of pancreatic cancer. Various cytokines, growth factors and environmental stimuli have been identified to activate STAT3. Attenuation of malignant transformation susceptibility of different cell types was noted on inhibition of STAT3 activation; thus, STAT3 has been put forward as a possible drug target for pancreatic cancer therapy. Several inhibitors have been proposed to regulate the upstream positive or negative control elements of STAT3 activation and target STAT3 directly. However, it is imperative to explore further for the effective STAT3 inhibitors that could improve the clinical outcome in patients with pancreatic cancer.

Keywords

Pancreatic cancer Activated STAT3 STAT3 inhibitors Cancer targets 

Notes

Acknowledgements

The authors gratefully acknowledge the Science and engineering research board, Department of science and technology, Government of India and Indian Council of Medical Research, New Delhi, for the research fellowships.

Conflict of Interests

We declare that we do not have any conflict of interests.

References

  1. 1.
    Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T,…, Kishimoto T (1994) Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77(1): 63–71Google Scholar
  2. 2.
    Andersen JN, Mortensen OH, Peters GH, Drake PG, Iversen LF, Olsen OH, …, Moller NP (2001) Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol Cell Biol 21(21): 7117–7136. doi:  https://doi.org/10.1128/MCB.21.21.7117-7136.2001
  3. 3.
    Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr (1999) Stat3 as an oncogene. Cell 98(3):295–303CrossRefPubMedGoogle Scholar
  4. 4.
    Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K,…, Watson CJ (1999) Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13(19): 2604–2616Google Scholar
  5. 5.
    Chen W, Daines MO, Khurana Hershey GK (2004) Turning off signal transducer and activator of transcription (STAT): the negative regulation of STAT signaling. J Allergy Clin Immunol 114(3):476–489.; quiz 490.  https://doi.org/10.1016/j.jaci.2004.06.042 CrossRefPubMedGoogle Scholar
  6. 6.
    Croker BA, Kiu H, Nicholson SE (2008) SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 19(4):414–422.  https://doi.org/10.1016/j.semcdb.2008.07.010 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19(1):1–11CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Darnell JE Jr (1997) STATs and gene regulation. Science 277(5332):1630–1635CrossRefPubMedGoogle Scholar
  9. 9.
    Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, Bromberg JF (2004) Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 101(29):10602–10607.  https://doi.org/10.1073/pnas.0404100101 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Edderkaoui M, Eibl G (2014) Risk factors for pancreatic cancer: underlying mechanisms and potential targets. Front Physiol 5:490.  https://doi.org/10.3389/fphys.2014.00490 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Feng Z (2010) p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb Perspect Biol 2(2):a001057.  https://doi.org/10.1101/cshperspect.a001057 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Frank DA (2007) STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 251(2):199–210.  https://doi.org/10.1016/j.canlet.2006.10.017 CrossRefPubMedGoogle Scholar
  13. 13.
    Furqan M, Mukhi N, Lee B, Liu D (2013) Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res 1(1):5.  https://doi.org/10.1186/2050-7771-1-5 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Gassmann P, Haier J (2008) The tumor cell-host organ interface in the early onset of metastatic organ colonisation. Clin Exp Metastasis 25(2):171–181.  https://doi.org/10.1007/s10585-007-9130-6 CrossRefPubMedGoogle Scholar
  15. 15.
    Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899.  https://doi.org/10.1016/j.cell.2010.01.025 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Groner B, Lucks P, Borghouts C (2008) The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol 19(4):341–350.  https://doi.org/10.1016/j.semcdb.2008.06.005 CrossRefPubMedGoogle Scholar
  17. 17.
    Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS (1999) Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 59(7):1592–1598PubMedGoogle Scholar
  18. 18.
    Huang S (2007) Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res: Off J Am Assoc Cancer Res 13(5):1362–1366.  https://doi.org/10.1158/1078-0432.CCR-06-2313 CrossRefGoogle Scholar
  19. 19.
    Ihle JN (2001) The stat family in cytokine signaling. Curr Opin Cell Biol 13(2):211–217CrossRefPubMedGoogle Scholar
  20. 20.
    Itoh M, Murata T, Suzuki T, Shindoh M, Nakajima K, Imai K, Yoshida K (2006) Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 25(8):1195–1204.  https://doi.org/10.1038/sj.onc.1209149 CrossRefPubMedGoogle Scholar
  21. 21.
    Kamran MZ, Patil P, Gude RP (2013) Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int 2013:421821.  https://doi.org/10.1155/2013/421821 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kojima H, Sasaki T, Ishitani T, Iemura S, Zhao H, Kaneko S, …, Nakajima K (2005) STAT3 regulates Nemo-like kinase by mediating its interaction with IL-6-stimulated TGFbeta-activated kinase 1 for STAT3 Ser-727 phosphorylation. Proc Natl Acad Sci USA 102(12): 4524–4529. doi:  https://doi.org/10.1073/pnas.0500679102
  23. 23.
    Kolodecik T, Shugrue C, Ashat M, Thrower EC (2013) Risk factors for pancreatic cancer: underlying mechanisms and potential targets. Front Physiol 4:415.  https://doi.org/10.3389/fphys.2013.00415 PubMedGoogle Scholar
  24. 24.
    Konig J, Hartel M, Nies AT, Martignoni ME, Guo J, Buchler MW, …, Keppler D (2005) Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 115(3): 359–367. doi:  https://doi.org/10.1002/ijc.20831
  25. 25.
    Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, …, Mustjoki S (2012) Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 366(20): 1905–1913. doi:  https://doi.org/10.1056/NEJMoa1114885
  26. 26.
    Leaman DW, Leung S, Li X, Stark GR (1996) Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J: Off Publ Fed Am Soc Exp Biol 10(14):1578–1588CrossRefGoogle Scholar
  27. 27.
    Lee JY, Hennighausen L (2005) The transcription factor Stat3 is dispensable for pancreatic beta-cell development and function. Biochem Biophys Res Commun 334(3):764–768.  https://doi.org/10.1016/j.bbrc.2005.06.162 CrossRefPubMedGoogle Scholar
  28. 28.
    Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, …, Algul H (2011) Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19(4): 456–469. doi:  https://doi.org/10.1016/j.ccr.2011.03.009
  29. 29.
    Lu Z, Kleeff J, Shrikhande S, Zimmermann T, Korc M, Friess H, Buchler MW (2000) Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas 21(3):240–247CrossRefPubMedGoogle Scholar
  30. 30.
    Miyatsuka T, Kaneto H, Shiraiwa T, Matsuoka TA, Yamamoto K, Kato K, …, Fujitani Y (2006) Persistent expression of PDX-1 in the pancreas causes acinar-to-ductal metaplasia through Stat3 activation. Genes Dev 20(11): 1435–1440. doi:  https://doi.org/10.1101/gad.1412806
  31. 31.
    Neesse A, Krug S, Gress TM, Tuveson DA, Michl P (2013) Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. OncoTargets Ther 7:33–43.  https://doi.org/10.2147/OTT.S38111 CrossRefGoogle Scholar
  32. 32.
    Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R,…, Yu H (2005) Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25(17): 7432–7440. doi:  https://doi.org/10.1128/MCB.25.17.7432-7440.2005
  33. 33.
    Oh MK, Park HJ, Kim NH, Park SJ, Park IY, Kim IS (2011) Hypoxia-inducible factor-1alpha enhances haptoglobin gene expression by improving binding of STAT3 to the promoter. J Biol Chem 286(11):8857–8865.  https://doi.org/10.1074/jbc.M110.150557 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V,…, Zucman-Rossi J (2011) Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med 208(7): 1359–1366. doi:  https://doi.org/10.1084/jem.20110283
  35. 35.
    Rakesh S, Narinder S, Sharmila S (2014) STAT3 as an emerging molecular target in pancreatic cancer. Gastrointest Cancer: Targets Ther 4:115.  https://doi.org/10.2147/gictt.s48993 Google Scholar
  36. 36.
    Scholz A, Heinze S, Detjen KM, Peters M, Welzel M, Hauff P,…, Rosewicz S (2003) Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 125(3): 891–905Google Scholar
  37. 37.
    Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721–732.  https://doi.org/10.1038/nrc1187 CrossRefPubMedGoogle Scholar
  38. 38.
    Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T (1999) Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 11(6):709–719CrossRefPubMedGoogle Scholar
  39. 39.
    Shuai K, Liu B (2005) Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol 5(8):593–605.  https://doi.org/10.1038/nri1667 CrossRefPubMedGoogle Scholar
  40. 40.
    Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ,…, Hilton DJ (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387(6636): 917–921. doi:  https://doi.org/10.1038/43206
  41. 41.
    Steele CW, Jamieson NB, Evans TR, McKay CJ, Sansom OJ, Morton JP, Carter CR (2013) Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer 108(5):997–1003.  https://doi.org/10.1038/bjc.2013.24 CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Thomas SJ, Snowden JA, Zeidler MP, Danson SJ (2015) The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer 113(3):365–371.  https://doi.org/10.1038/bjc.2015.233 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Vicari AP, Caux C, Trinchieri G (2002) Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 12(1):33–42.  https://doi.org/10.1006/scbi.2001.0400 CrossRefPubMedGoogle Scholar
  44. 44.
    Vitale G, Zappavigna S, Marra M, Dicitore A, Meschini S, Condello M,…, Caraglia M (2012) The PPAR-gamma agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-beta treated pancreatic cancer cells. Biotechnol Adv 30(1): 169–184. doi:  https://doi.org/10.1016/j.biotechadv.2011.08.001
  45. 45.
    Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S,…, Yu H (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10(1): 48–54. doi:  https://doi.org/10.1038/nm976
  46. 46.
    Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC et al (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22(3):319–329.  https://doi.org/10.1038/sj.onc.1206122 CrossRefPubMedGoogle Scholar
  47. 47.
    Yadav D, Lowenfels AB (2013) The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 144(6):1252–1261.  https://doi.org/10.1053/j.gastro.2013.01.068 CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Yahata Y, Shirakata Y, Tokumaru S, Yamasaki K, Sayama K, Hanakawa Y,…, Hashimoto K (2003) Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J Biol Chem 278(41): 40026–40031. doi:  https://doi.org/10.1074/jbc.M301866200
  49. 49.
    Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7(1):41–51.  https://doi.org/10.1038/nri1995 CrossRefPubMedGoogle Scholar
  50. 50.
    Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798–809.  https://doi.org/10.1038/nrc2734 CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Yuan ZL, Guan YJ, Chatterjee D, Chin YE (2005) Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307(5707):269–273.  https://doi.org/10.1126/science.1105166 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd 2017

Authors and Affiliations

  • Rongala Laxmivandana
    • 1
    • 2
  • Prudhvi Lal Bhukya
    • 3
  • Maddala Madhavi
    • 4
  1. 1.N-PDF, SERB-DSTNew DelhiIndia
  2. 2.ICAR-IIABRanchiIndia
  3. 3.National Institute of VirologyPuneIndia
  4. 4.Department of Zoology, Nizam CollegeOsmania UniversityHyderabadIndia

Personalised recommendations